Tidal Investments LLC boosted its stake in Tilray Inc (NASDAQ:TLRY - Free Report) by 9.2% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 10,595,264 shares of the company's stock after buying an additional 889,086 shares during the quarter. Tidal Investments LLC owned approximately 1.13% of Tilray worth $14,092,000 as of its most recent filing with the SEC.
A number of other large investors have also recently bought and sold shares of the stock. Lido Advisors LLC acquired a new stake in shares of Tilray during the fourth quarter valued at $28,000. Dudley Capital Management LLC purchased a new position in Tilray during the fourth quarter worth about $29,000. Verdence Capital Advisors LLC acquired a new stake in Tilray in the 4th quarter worth about $29,000. Ameritas Advisory Services LLC acquired a new position in shares of Tilray during the 4th quarter valued at about $32,000. Finally, Newman Dignan & Sheerar Inc. lifted its holdings in shares of Tilray by 61.9% during the 4th quarter. Newman Dignan & Sheerar Inc. now owns 26,150 shares of the company's stock worth $35,000 after acquiring an additional 10,000 shares during the period. Institutional investors and hedge funds own 9.35% of the company's stock.
Tilray Trading Down 3.6%
Shares of NASDAQ:TLRY traded down $0.02 during trading on Friday, reaching $0.43. 9,235,641 shares of the stock were exchanged, compared to its average volume of 35,306,973. Tilray Inc has a 12-month low of $0.41 and a 12-month high of $2.15. The firm's 50-day moving average price is $0.52 and its 200 day moving average price is $0.93. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.58 and a current ratio of 2.54. The firm has a market cap of $433.80 million, a price-to-earnings ratio of -1.44 and a beta of 1.95.
Tilray (NASDAQ:TLRY - Get Free Report) last released its quarterly earnings data on Tuesday, April 8th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.06). The business had revenue of $185.78 million during the quarter, compared to analyst estimates of $213.38 million. Tilray had a negative return on equity of 4.40% and a negative net margin of 30.95%. On average, sell-side analysts anticipate that Tilray Inc will post -0.2 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of research firms recently issued reports on TLRY. Roth Capital restated a "neutral" rating on shares of Tilray in a report on Monday, April 14th. Piper Sandler cut their target price on Tilray from $2.00 to $1.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 9th.
Read Our Latest Stock Report on TLRY
Tilray Company Profile
(
Free Report)
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.
Featured Articles
Before you consider Tilray, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tilray wasn't on the list.
While Tilray currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
